uPAR-PET for prognostication in patients with non-small cell lung cancer, malignant pleural mesothelioma and large cell neuroendocrine carcinoma of the lung

Phase 1

Conditions: on-small cell lung cancer, malignant pleural mesothelioma, large cell neuroendocrine carcinoma of the lung
MedDRA version: 18.1Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA version: 18.1Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]

Registration Number: EUCTR2015-005642-59-DK

Lead Sponsor: Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

Study I:
- Histologically verified NSCLC
- Stage IV disease
- Operable disease
- Age above 18
- The participants must be capable of understanding and giving full informed written consent

Study II:
- Histologically verified MPM
- Age above 18
- The participants must be capable of understanding and giving full informed written consent

Study III:
- Histologically verified LCNEC
- Age above 18
- The participants must be capable of understanding and giving full informed written consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 60
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 60

Exclusion Criteria

Study I, II, III:
- Pregnancy
- Lactation/breast feeding
- Age above 85 years
- Weight above 140 kg
- Treatment with neoadjuvant chemotherapy
- Allergy to 68Ga-NOTA-AE105